Wall Street brokerages expect Tcr2 Therapeutics Inc (NASDAQ:TCRR) to announce ($0.58) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.64). Tcr2 Therapeutics reported earnings of ($0.46) per share during the same quarter last year, which would indicate a negative year over year growth rate of 26.1%. The firm is expected to announce its next quarterly earnings report on Thursday, August 13th.
According to Zacks, analysts expect that Tcr2 Therapeutics will report full-year earnings of ($2.47) per share for the current year, with EPS estimates ranging from ($2.86) to ($2.11). For the next year, analysts expect that the firm will report earnings of ($2.49) per share, with EPS estimates ranging from ($3.08) to ($1.98). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Tcr2 Therapeutics.
Tcr2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05).
In other Tcr2 Therapeutics news, Director Neil W. Gibson sold 17,723 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $6.60, for a total transaction of $116,971.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Neil W. Gibson sold 52,000 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $6.52, for a total value of $339,040.00. The disclosure for this sale can be found here. Insiders have sold 73,491 shares of company stock valued at $482,467 in the last ninety days. 39.07% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of TCRR. EcoR1 Capital LLC acquired a new position in Tcr2 Therapeutics during the fourth quarter worth about $3,420,000. ArrowMark Colorado Holdings LLC raised its stake in Tcr2 Therapeutics by 12.7% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,269,766 shares of the company’s stock worth $18,132,000 after acquiring an additional 143,459 shares in the last quarter. DAFNA Capital Management LLC acquired a new position in Tcr2 Therapeutics during the first quarter worth about $610,000. Victory Capital Management Inc. raised its stake in Tcr2 Therapeutics by 572.4% during the fourth quarter. Victory Capital Management Inc. now owns 86,432 shares of the company’s stock worth $1,234,000 after acquiring an additional 73,578 shares in the last quarter. Finally, Boston Private Wealth LLC acquired a new position in shares of Tcr2 Therapeutics in the fourth quarter valued at approximately $699,000. 59.22% of the stock is owned by hedge funds and other institutional investors.
TCRR stock traded down $0.10 during midday trading on Friday, reaching $10.10. 112,520 shares of the company were exchanged, compared to its average volume of 102,721. The business has a 50-day moving average price of $10.08 and a two-hundred day moving average price of $12.66. Tcr2 Therapeutics has a one year low of $5.84 and a one year high of $21.06. The firm has a market capitalization of $243.17 million, a price-to-earnings ratio of -4.53 and a beta of 1.76.
About Tcr2 Therapeutics
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Further Reading: Is it better to buy a fund with a higher or lower NAV?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.